

Supplemental materials

Supplemental Table 1. Relative risks of siblings and mothers for a specific type of early-onset cancer (diagnosed 0 to 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.

Cancer of the proband <sup>†</sup>	Cancer of the relative <sup>§</sup>	No. of affected relatives <sup>§</sup>	SIR (95% CI)
	Leukemias	11	2.48 (0.98, 6.31)
	Lymphomas	6	2.46 (0.7, 8.61)
	CNS tumors	6	2.02 (0.65, 6.3)
	VII. Hepatic tumors	1	0.41 (0.12, 1.43)
	Sarcomas	8	<b>7.36* (1.12, 48.23)</b>
	GCT	6	3.51 (0.78, 15.72)
<b>Leukemias</b>	Epithelial neoplasms	13	<b>5.37* (1.52, 18.92)</b>
	Leukemias	7	7.47 (0.99, 56.59)
	Lymphomas	4	5.9 (0.55, 63.77)
	CNS tumors	2	2.89 (0.27, 30.59)
	Neuroblastoma	1	15.38 (0.01, 33561.02)
	Retinoblastoma	1	40 (0, 9674536.43)
	Renal tumors	1	12.99 (0.01, 15173.41)
	Sarcomas	2	7.07 (0.18, 281.41)
	GCT	1	1.93 (0.13, 29.54)
<b>Lymphomas</b>	Epithelial neoplasms	2	2.67 (0.28, 25.71)
	Leukemias	5	1.94 (0.57, 6.58)
	Lymphomas	2	1.31 (0.27, 6.36)
	CNS tumors	11	<b>6.19* (1.42, 26.93)</b>
	Renal tumors	1	4.29 (0.07, 248.94)
	Sarcomas	6	8.97 (0.82, 98.5)
	GCT	2	1.81 (0.28, 11.72)
<b>CNS tumors</b>	Epithelial neoplasms	10	<b>6.37* (1.33, 30.41)</b>

	Other	1	0.65 (0.13, 3.18)
	Lymphomas	1	2.23 (0.12, 41.5)
	Neuroblastoma	1	10.31 (0.02, 5575.99)
	Sarcomas	1	4.78 (0.07, 348.18)
	GCT	1	3.33 (0.09, 119.39)
	Epithelial neoplasms	2	5.09 (0.22, 116)
<b>Neuroblastoma</b>	Other	1	2.23 (0.12, 41.5)
	Lymphomas	1	4.5 (0.07, 288.57)
	Retinoblastoma	10	454.55 (0, 249162343.25)
	VIII. Malignant bone tumors	1	4.5 (0.07, 288.57)
	Sarcomas	1	9.52 (0.02, 4033.89)
<b>Retinoblastoma</b>	Epithelial neoplasms	1	5.24 (0.06, 464.17)
	Lymphomas	1	3.02 (0.1, 91.14)
	CNS tumors	1	2.37 (0.12, 48.42)
	Renal tumors	1	15.87 (0.01, 39083.18)
	Sarcomas	2	13.33 (0.08, 2102.67)
	GCT	1	4.42 (0.07, 273.17)
<b>Renal tumors</b>	Epithelial neoplasms	3	9.17 (0.3, 282.58)
	Leukemias	1	4.08 (0.08, 214.07)
<b>VII. Hepatic tumors</b>	Epithelial neoplasms	1	9.52 (0.02, 4033.89)
	Leukemias	1	14.49 (0.01, 25216.18)
<b>VIII. Malignant bone tumors</b>	Epithelial neoplasms	1	16.39 (0.01, 45829.78)
	Leukemias	8	<b>7.01* (1.12, 43.92)</b>
	Lymphomas	1	1.37 (0.14, 13.5)
	CNS tumors	7	8.62 (0.98, 75.89)
	Neuroblastoma	1	11.11 (0.02, 7640.96)
	Renal tumors	2	19.8 (0.04, 9443.54)
	Sarcomas	10	31.45 (0.97, 1016.37)
<b>Sarcomas</b>	GCT	4	7.41 (0.51, 106.67)

	Epithelial neoplasms	6	7.56 (0.84, 68.17)
	Other	1	1.37 (0.14, 13.5)
	Leukemias	4	5.81 (0.55, 61.76)
	Lymphomas	2	4.06 (0.25, 66.15)
	CNS tumors	3	5.93 (0.38, 93.24)
	Neuroblastoma	1	19.23 (0, 103951.54)
	Renal tumors	1	16.67 (0.01, 49765.5)
	Sarcomas	2	9.66 (0.13, 717.76)
	GCT	3	7.71 (0.33, 178.63)
<b>GCT</b>	Epithelial neoplasms	4	6.92 (0.53, 91.15)
	Leukemias	4	8.39 (0.49, 143.23)
	Lymphomas	1	2.19 (0.12, 39.96)
	CNS tumors	3	7.56 (0.34, 169.55)
	Neuroblastoma	1	41.67 (0, 13012839.04)
	Sarcomas	2	10.99 (0.11, 1087.03)
	GCT	1	2.63 (0.11, 63.25)
<b>Epithelial neoplasms</b>	Epithelial neoplasms	24	<b>40.68* (3.17, 521.85)</b>
	Lymphomas	1	16.39 (0.01, 45829.78)
	CNS tumors	1	14.29 (0.01, 23561.37)
	Neuroblastoma	1	125 (0, 410967476948.84)
<b>Other</b>	Sarcomas	1	37.04 (0, 5610209.13)

† Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

§ Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age. SIR, Standardized incidence ratio. CI, confidence interval.

\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.



			(0.12, 932.36)					8	0	NA	NA	19	0	NA	0.065
Hematologic cancers <sup>†</sup>	2702	19	<b>2.69*</b> <b>(1.29, 5.62)</b>	5484	27	<b>2.48*</b> <b>(1.37, 4.50)</b>	<b>0.016</b>	679	8	<b>7.56* (1.12, &lt;0.00 50.83)</b>	<b>1</b>	391	4	6.15 (0.54, 69.81)	<b>&lt;0.001</b>
Solid cancers <sup>†</sup>	5471	37	<b>3.02*</b> <b>(1.72, 5.28)</b>	7323	62	<b>4.98*</b> <b>(2.86, 8.68)</b>	<b>0.001</b>	1021	7	5.07 (0.96, <0.00 26.88)	<b>1</b>	719	9	<b>7.35*</b> <b>(1.25, 43.2)</b>	<b>&lt;0.001</b>

<sup>†</sup> Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

<sup>§</sup> Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

<sup>‡</sup> p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

<sup>††</sup> Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.

**Supplementary Table 3. Relative risks of the same type of early-onset cancer with the proband among siblings and mothers by ethnic group, 1989 to 2015, California, USA.**

Cancer of the proband †	Overall			Non-Latino White			Latino all races			p-value ‡
	No. of Probands	No. of affected relatives §	SIR (95% CI)	No. of Probands	No. of affected relatives §	SIR (95% CI)	No. of Probands	No. of affected relatives §	SIR (95% CI)	
Leukemias	8500	11	2.48 (0.98, 6.31)	1646	2	2.19 (0.28, 17.02)	4374	4	1.45 (0.45, 4.74)	0.083
Lymphomas	2928	4	5.90 (0.55, 63.82)	1060	3	9.03 (0.3, 270.64)	1121	0	NA	NA
CNS tumors	5739	11	<b>6.19*</b> (1.42, 26.93)	1728	4	5.07 (0.56, 46.02)	2242	3	4.66 (0.41, 53.56)	0.483
Neuroblastoma	1445	1	10.28 (0.02, 5501.95)	367	0	NA	490	0	NA	NA
Retinoblastoma	718	10	446.17 (0, 216413526.63)	126	1	194.8 (0, 1479721536316.56)	327	7	662.31 (0, 126150580638.22)	<b>0.009</b>
Renal tumors	1069	1	15.95 (0.01, 39978.15)	209	0	NA	442	1	39.09 (0, 8211440.71)	NA
VII. Hepatic tumors	414	0	NA	74	0	NA	200	0	NA	NA
VIII. Malignant bone tumors	249	0	NA	73	0	NA	121	0	NA	NA
Sarcomas	2915	10	31.49 (0.97, 1020.26)	816	2	18.88 (0.05, 7792.14)	1259	5	35.96 (0.19, 6895.34)	0.155
GCT	2423	3	7.71 (0.33, 178.48)	672	0	NA	1270	2	8.63 (0.15, 506.54)	NA
Epithelial neoplasms	3050	24	<b>40.68*</b> (3.17, 521.78)	1458	9	21.31 (1.04, 434.91)	1046	9	55.65 (0.43, 7278.24)	<b>&lt;0.001</b>
Other	255	0	NA	79	0	NA	90	0	NA	NA
Hematologic cancers¶	11404	22	<b>2.68*</b> (1.35, 5.32)	2702	6	2.64 (0.72, 9.71)	5484	7	1.56 (0.62, 3.94)	0.133
Solid cancers¶	17849	112	<b>6.78*</b> (4.18, 10.98)	5471	31	<b>4.41*</b> (2.10, 9.23)	7323	50	<b>7.94*</b> (3.64, 17.34)	<b>0.005</b>

† Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

§ Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

‡ p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

¶ Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.

Supplemental Table 4. Relative risks of any early-onset cancer (diagnosed at 0 to 26 years of age) for siblings and mothers of the same type of cancer with the proband given a proband with cancer by subgroups, 1989 to 2015, California, USA.

Cancer of the proband <sup>†</sup>	All cancers			The same type of cancer	
	No. of probands	No. of affected relatives <sup>§</sup>	SIR (95% CI)	No. of affected relatives <sup>§</sup>	SIR (95% CI)
			<b>2.70*</b>		1.86
Lymphoid leukemias	6705	25	<b>(1.60, 4.55)</b>	5	(0.04, 77.51)
Acute myeloid leukemias	1317	9	<b>4.61*</b> <b>(1.44, 14.83)</b>	3	26.35 (0.21, 3254.81)
Hodgkin lymphomas	1399	9	<b>7.12*</b> <b>(1.67, 30.35)</b>	2	10.30 (0.03, 3755.90)
Non-Hodgkin lymphomas (except Burkitt lymphoma)	985	5	4.02 (0.81, 20.01)	1	11.35 (0.00, 47646.79)
Ependymomas and choroid plexus tumor	561	2	2.46 (0.42, 14.51)	0	NA
Astrocytomas	1965	11	<b>3.60*</b> <b>(1.33, 9.71)</b>	2	7.62 (0.02, 2780.03)
Intracranial and intraspinal embryonal tumors	1010	6	2.67 (0.80, 8.96)	1	11.70 (0.00, 49115.47)
Other gliomas	815	8	<b>5.34*</b> <b>(1.08, 26.52)</b>	2	58.00 (0.16, 21151.56)
Other specified intracranial and intraspinal neoplasms	1470	5	<b>5.48*</b> <b>(1.19, 25.27)</b>	2	22.91 (0.06, 8355.61)
Neuroblastoma and ganglioneuroblastoma	1409	6	2.06 (0.71, 5.97)	1	8.95 (0.00, 37570.97)
Nephroblastoma and other nonepithelial renal tumors	1032	6	<b>3.67*</b> <b>(1.05, 12.83)</b>	1	16.42 (0.00, 68950.65)
Rhabdomyosarcomas	719	11	<b>8.46*</b> <b>(1.84, 38.84)</b>	0	NA
Fibrosarcomas to peripheral nerve sheath tumors to and other fibrous neoplasms	434	7	10.46 (0.95, 114.82)	2	<b>390.23*</b> <b>(1.07, 142319.04)</b>
Other specified soft tissue sarcomas	1624	11	<b>7.57*</b> <b>(2.20, 26.07)</b>	5	<b>58.45</b> <b>(1.40, 2438.32)</b>
Malignant gonadal germ cell tumors	1030	12	<b>5.44*</b> <b>(1.67, 17.71)</b>	2	6.69 (0.02, 2439.81)
Malignant melanomas	788	2	3.65 (0.42, 31.77)	1	22.34 (0.01, 93804.63)



<b>Other and unspecified carcinomas</b>	1845	20	<b>18.12*</b> <b>(3.85, 85.29)</b>	17	<b>115.36*</b> <b>(15.25, 872.55)</b>
---	------	----	---------------------------------------	----	--

†Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

§ Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

SIR, Standardized incidence ratio. CI, confidence interval.

\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.

Supplementary Table 5. Relative risks of all pediatric cancers (diagnosed 0 to 15 years of age) among siblings and mothers by ethnic group, 1989 to 2015, California, USA.

Cancer of the proband †	Overall			Non-Latino White			Latino all races			p-value ‡
	No. of Probands	No. of affected relatives §	SIR (95% CI)	No. of Probands	No. of affected relatives §	SIR (95% CI)	No. of Probands	No. of affected relatives §	SIR (95% CI)	
<b>Overall</b>	29072	72	<b>1.56*</b> (1.17, 2.08)	8119	18	0.93 (0.60, 1.46)	12736	35	<b>1.51*</b> (1.00, 2.26)	<b>0.003</b>
<b>Leukemias</b>	8500	22	1.40 (0.85, 2.29)	1646	2	0.38 (0.16, 0.90)	4374	11	1.23 (0.64, 2.37)	<b>0.003</b>
<b>Lymphomas</b>	2928	11	<b>2.88*</b> (1.06, 7.86)	1060	4	2.15 (0.51, 9.08)	1121	4	2.04 (0.50, 8.28)	0.916
<b>CNS tumors</b>	5739	23	<b>2.42*</b> (1.28, 4.57)	1728	7	1.53 (0.61, 3.83)	2242	5	1.19 (0.46, 3.09)	0.359
<b>Neuroblastoma</b>	1445	5	1.57 (0.52, 4.70)	367	0	NA	490	1	0.85 (0.14, 5.16)	0.313
<b>Retinoblastoma</b>	718	11	<b>6.79*</b> (1.46, 31.64)	126	1	1.81 (0.13, 25.25)	327	8	<b>10.95*</b> (1.11, 108.43)	<b>0.011</b>
<b>Renal tumors</b>	1069	4	1.81 (0.48, 6.77)	209	0	NA	442	3	2.91 (0.42, 20.03)	0.077
<b>VII. Hepatic tumors</b>	414	1	1.20 (0.14, 10.2)	74	0	NA	200	0	NA	NA
<b>VIII. Malignant bone tumors</b>	249	1	3.28 (0.09, 114.19)	73	0	NA	121	1	6.06 (0.05, 755.63)	0.306
<b>Sarcomas</b>	2915	23	<b>5.25*</b> (2.06, 13.41)	816	4	2.15 (0.51, 9.04)	1259	11	<b>4.96*</b> (1.33, 18.52)	<b>0.031</b>
<b>GCT</b>	2423	13	<b>4.70</b> (1.45, 15.29)	672	3	2.57 (0.42, 15.72)	1270	7	4.33 (0.93, 20.25)	0.098
<b>Epithelial neoplasms</b>	3050	13	<b>5.83*</b> (1.57, 21.67)	1458	6	3.67 (0.79, 16.98)	1046	5	5.03 (0.70, 35.87)	0.165
<b>Other</b>	255	3	8.03 (0.33, 198.63)	79	2	10.49 (0.12, 932.36)	90	1	5.86 (0.05, 673.74)	0.313
<b>Hematologic cancers¶</b>	11404	29	1.48 (0.95, 2.31)	2702	6	0.85 (0.41, 1.76)	5484	13	1.19 (0.66, 2.16)	<b>0.023</b>
<b>Solid cancers¶</b>	17849	71	<b>2.64*</b> (1.81, 3.86)	5471	18	1.46 (0.84, 2.56)	7323	32	<b>2.57*</b> (1.47, 4.47)	<b>0.013</b>

† Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

§ Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

‡ p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

¶ Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.

**Supplemental Table 6. Relative risks of second primary malignancies of the same type of early-onset cancer (diagnosed 0 to 26 years of age) with the first primary malignancy by ethnic groups, California, USA.**

Cancer of the proband †	Overall			Non-Latino White			Latino (all races)			p-value ‡
	No. of FPMs	No. of SPMs	SIR (95% CI)	No. of FPMs	No. of SPMs	SIR (95% CI)	No. of FPMs	No. of SPMs	SIR (95% CI)	
			9.27*			12.05			5.82	
<b>Leukemias</b>	8,543	41	<b>(3.65 to 23.56)</b>	1,649	11	(1.55 to 93.71)	4,385	16	(1.78 to 18.96)	<b>0.001</b>
			13.27*			12.05			11.29	
<b>Lymphomas</b>	2,960	9	<b>(1.23 to 143.48)</b>	1,063	4	(0.40 to 361.60)	1,124	3	(0.25 to 505.82)	
			16.39*			15.19			17.08	
<b>CNS tumors</b>	5,877	29	<b>(3.76 to 71.56)</b>	1,765	12	(1.67 to 137.80)	2,277	11	(1.49 to 196.43)	0.431
			20.62			51.28				
<b>Neuroblastoma</b>	1,450	2	(0.04 to 11151.98)	369	2	(0.00 to 1047532.66)	491	0	NA	
<b>Retinoblastoma</b>	728	0		127	0	NA	334	0	NA	
<b>Renal tumors</b>	1,078	0		209	0	NA	444	0	NA	
<b>VII. Hepatic tumors</b>	417	0		74	0	NA	200	0	NA	
<b>VIII. Malignant bone tumors</b>	250	0		73	0	NA	121	0	NA	
			50.31*			47.17			50.36	
<b>Sarcomas</b>	3,028	16	<b>(1.56 to 1626.19)</b>	850	5	(0.11 to 19415.87)	1,297	7	(0.26 to 9665.53)	0.353
			5.14						8.62	
<b>GCT</b>	2,468	2	(0.22 to 119.09)	679	0	NA	1,287	2	(0.15 to 504.41)	
<b>Epithelial neoplasms</b>	3,479	10	<b>(1.32 to 217.44)</b>	1,489	6	(0.70 to 288.80)	1,057	4	(0.19 to 3216.7)	<b>0.005</b>
<b>Other</b>	261	0		79	0	NA	90	0	NA	
<b>Hematologic cancers<sup>¶</sup></b>	11,553	50	<b>(3.08, 12.10)</b>	2,727	15	<b>(1.80, 24.29)</b>	5,528	19	<b>(1.68, 10.68)</b>	<b>0.012</b>
			1.82*			1.85			2.06	
<b>Solid cancers<sup>¶</sup></b>	18,893	30	<b>(1.12, 2.94)</b>	5,673	13	(0.88, 3.87)	7,551	13	(0.95, 4.51)	0.681

SIR, Standardized incidence ratio. CI, confidence interval. FPM, first primary malignancy. SPM, second primary malignancy.

† Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<https://seer.cancer.gov/iccc/iccc3.html>).

‡ p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

¶ Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval. FPM, first primary malignancy. SPM, second primary malignancy.  
\* Statistically significant standardized incidence ratio with  $p < 0.05$  assuming a Poisson distribution.

### **Supplemental Figure legends**

#### **Supplemental Figure 1. Relative risks of all cancers for mothers given a proband with cancer.**

A. Relative risks of all cancers for mothers given a proband with cancer by 5-year age group.

B. Age-adjusted incidence rate of all cancers by ethnic group in SEER 13.

AAIR in SEER 13, age-adjusted incidence rate of all cancers among females derived from the Surveillance, Epidemiology, and End Results (SEER) Program version 13 among female patients diagnosed in California between 1992 to 2015.


The axis for SIR was natural log-transformed. The error bars represent natural log-transformed upper and lower confidence limits of the SIR. Age (years) represent the age of first primary cancer diagnosis for a mother.

The SIR was 5.89 (95% CI: 4.25 to 8.16) for all mother cases age 15-39; 17.56 (95% CI: 6.24 to 49.42) for non-Latino White mother cases age 15-39; 5.19 (95% CI: 3.24 to 8.31) for Latino mother cases age 15-39.

\* P-value < 0.001 comparing the SIR of age 15-39 for non-Latino White to Latino subjects using an approximate Chi-square test.

Abbreviations: SIR, Standardized incidence ratio. AAIR: age-adjusted incidence rate. SEER 13, Surveillance, Epidemiology, and End Results Program version 13.

Supplementary Figure 1A.



Supplementary Figure 1B.

